These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 25907003)

  • 21. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
    Roehrborn CG; Manyak MJ; Palacios-Moreno JM; Wilson TH; Roos EPM; Santos JC; Karanastasis D; Plastino J; Giuliano F; Rosen RC
    BJU Int; 2018 Apr; 121(4):647-658. PubMed ID: 29044968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage.
    Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Prokofyeva A; Loparev S
    Aging Male; 2018 Jun; 21(2):121-129. PubMed ID: 29113548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
    Robinson D; Kelleher C; Staskin D; Mueller ER; Falconer C; Wang J; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Hakimi Z; Herschorn S
    Neurourol Urodyn; 2018 Jan; 37(1):394-406. PubMed ID: 28704584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamsulosin/solifenacin fixed-dose combination tablet for the treatment of male lower urinary tract symptoms.
    Romancik M; Pandian S; Drake MJ
    Drugs Today (Barc); 2014 Dec; 50(12):803-11. PubMed ID: 25588085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
    Gao ZW; Xin SY; Zhang JG; Ren XQ; Shang YF; Zhang W; Li HB; Xiao F; Shao CS
    Zhonghua Nan Ke Xue; 2014 Mar; 20(3):239-43. PubMed ID: 24738461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
    Lojanapiwat B; Permpongkosol S
    Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis.
    Gong M; Dong W; Huang G; Gong Z; Deng D; Qiu S; Yuan R
    Curr Med Res Opin; 2015; 31(9):1781-92. PubMed ID: 26211817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
    Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
    J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin.
    Ko K; Yang DY; Lee WK; Kim SW; Moon du G; Moon KH; Park NC; Park JK; Son HC; Lee SW; Hyun JS; Park K
    Korean J Urol; 2014 Sep; 55(9):608-14. PubMed ID: 25237463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with tamsulosin and solifenacin for male lower urinary tract symptoms with predominant filling symptoms: a new approach to an old problem.
    Angulo JC
    Curr Med Res Opin; 2015 Nov; 31(11):1963-5. PubMed ID: 26368336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study.
    Henningsohn L; Kilany S; Svensson M; Jacobsen JL
    Aging Male; 2017 Dec; 20(4):266-276. PubMed ID: 28787230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
    Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
    Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.